Neoleukin Therapeutics, Inc

(NASDAQ:NLTX)

Latest On Neoleukin Therapeutics, Inc (NLTX):

Date/Time Type Description Signal Details
2023-04-19 13:32 ESTNewsNeoleukin Therapeutics: Strategic Review PlayN/A
2023-03-09 04:42 ESTNewsNeoleukin Therapeutics to cut 70% workforce, CEO steps downN/A
2022-11-15 22:49 ESTNewsNeoleukin Therapeutics GAAP EPS of -$0.24 beats by $0.07N/A
2022-11-15 22:49 ESTNewsNeoleukin cut to Hold at Stifel on plans to drop lead assetN/A
2022-09-12 21:44 ESTNewsNeoleukin draws double downgrade at BofA on limited near-term upsideN/A
2022-08-10 03:42 ESTNewsNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 03:42 ESTNewsNeoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 05:52 ESTNewsNeoleukin Therapeutics Q2 2022 Earnings PreviewN/A
2022-05-10 10:56 ESTNewsNeoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02N/A
2022-04-13 20:45 ESTNewsNeoleukin announces preclinical data for immunotherapy candidate NL-201, shares fallN/A
2022-03-02 04:28 ESTNewsNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-10 23:21 ESTNewsMerck in pact with Neoleukin to study Keytruda combo in cancer trialN/A
2021-11-24 02:51 ESTNewsNeoleukin Therapeutics (NLTX) Investor Presentation - SlideshowN/A
2021-08-28 08:31 ESTNewsNeoleukin Therapeutics closes more than 23% higher following CEO share buyN/A
2021-08-10 08:45 ESTNewsLooking Back In On Neoleukin TherapeuticsN/A
2021-08-06 07:48 ESTNewsNeoleukin Therapeutics EPS in-lineN/A
2021-03-26 13:09 ESTNewsNeoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-16 21:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.13 to $22.Neutral
2021-02-03 23:08 ESTNewsNeoleukin Therapeutics: De Novo Protein Design PlatformN/A
2021-01-08 20:39 ESTNewsNeoleukin drops on FDA clinical hold letter related to IND for cancer immunotherapyN/A
2021-01-06 08:16 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.71 to $22.13.Neutral
2020-12-25 02:27 ESTNewsBABA, FUBO, GEVO and NLTX among midday moversN/A
2020-12-18 15:55 ESTNewsNeoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising TechnologyN/A
2020-12-10 15:59 ESTNewsNeoleukin files U.S. trial application for early-stage solid tumor study with its lead protein immunotherapy CandidateN/A
2020-11-26 20:58 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 04:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 12:40 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-09 15:27 ESTNewsNeoleukin Therapeutics EPS beats by $0.19N/A
2020-11-08 00:20 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:37 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:32 ESTFinancialsCompany financials have been released.Neutral
2020-09-23 09:36 ESTAnalyst RatingThe Analyst Target Price has increased from $22.33 to $22.71.Buy
2020-09-17 05:38 ESTFinancialsCompany financials have been released.Neutral
2020-08-28 21:16 ESTFinancialsCompany financials have been released.Neutral
2020-08-25 01:23 ESTFinancialsCompany financials have been released.Neutral
2020-08-21 17:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-19 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 21:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 05:26 ESTAnalyst RatingThe Analyst Target Price has increased from $22 to $22.33.Buy
2020-08-12 21:46 ESTNewsNeoleukin Therapeutics EPS misses by $0.04N/A
2020-08-12 21:44 ESTNewsNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 21:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:17 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:53 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 17:17 ESTAnalyst RatingThe Analyst Target Price has increased from $20.17 to $22.Buy

About Neoleukin Therapeutics, Inc (NLTX):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NLTX Quotes by TradingView

See Advanced Chart

General

  • Name Neoleukin Therapeutics, Inc
  • Symbol NLTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 65
  • Fiscal Year EndDecember
  • IPO Date2014-03-07
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.neoleukin.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.62
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.29
  • Return on Assets -16%
  • Return on Equity -22%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 486.02 million
  • Analyst Target Price $22
  • Book Value Per Share $2.38
View More

Share Statistics

  • Shares Outstanding 41.93 million
  • Shares Float 21.3 million
  • % Held by Insiders 2029%
  • % Held by Institutions 66.22%
  • Shares Short 2.98 million
  • Shares Short Prior Month 3.22 million
  • Short Ratio 13.68
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 0.99
  • 52 Week High $18.13
  • 52 Week Low $7.1
  • 50 Day Moving Average 12.55
  • 200 Day Moving Average 12.52
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Neoleukin Therapeutics, Inc (NLTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Neoleukin Therapeutics, Inc (NLTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-09$N/A-$0.04-$0.2382.46%
2020-06-302020-08-12$N/A-$0.20-$0.16-23.46%
2020-03-312020-05-06$N/A-$0.18-$0.2423.73%
2019-12-312020-03-12$N/A-$0.23-$0.3737.84%
2019-09-302019-11-13$N/A-$0.44-$0.04-990%
2019-06-302019-08-01$N/A$0.00-$0.05100%
2019-03-312019-05-07$N/A-$0.09-$0.2360.87%
2018-12-312019-03-07$N/A-$0.20-$0.7974.68%
2018-09-302018-11-07$N/A-$0.64-$0.21-204.76%
2018-06-302018-08-08$25 million$0.12-$0.59120.34%
2018-03-312018-05-08$N/A-$0.62-$0.7112.06%
2017-12-312018-03-12$N/A-$0.69-$0.60-15%
2017-09-302017-11-08$N/A-$0.50-$0.5914.89%
2017-06-302017-08-08$N/A-$0.59-$0.51-15.12%
2017-03-312017-05-09$N/A-$0.36-$0.5129.76%
2016-12-312017-03-09$N/A-$0.48-$0.46-4.35%
2016-09-302016-11-09$N/A-$0.46-$0.5821.03%
2016-06-302016-08-04$N/A-$0.63-$0.39-61.54%
2016-03-312016-05-10$N/A-$0.39-$0.35-12.23%
2015-12-312016-03-14$N/A-$0.26-$0.3626.76%
2015-09-302015-11-10$N/A-$0.43-$0.454.44%
2015-06-302015-08-06$N/A-$0.44-$0.5621.43%
2015-03-312015-05-12$N/A-$0.60-$0.8125.93%
2014-12-312015-03-16-$0.78-$0.76-2.63%
2014-09-302014-11-04$N/A-$0.59-$0.45-31.11%
2014-06-302014-08-11$N/A-$0.51-$0.27-88.89%
2014-03-312014-05-13$N/A-$1.28-$0.44-190.91%

Neoleukin Therapeutics, Inc (NLTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Neoleukin Therapeutics, Inc (NLTX) Chart:

Neoleukin Therapeutics, Inc (NLTX) News:

Below you will find a list of latest news for Neoleukin Therapeutics, Inc (NLTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Neoleukin Therapeutics, Inc (NLTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-07-192.50CALL0 40FALSE00
2024-07-1950CALL0 2183.57FALSE00
2024-07-197.50CALL0 0206.52FALSE00
2024-07-192.50PUT0 0262.6TRUE00
2024-07-1950PUT0 0125.52TRUE00
2024-07-197.50PUT0 0109.2TRUE00

Latest NLTX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST38$0.9686
Jun 13, 2022 7:59 PM EST17$0.9686
Jun 13, 2022 7:59 PM EST59$0.9672
Jun 13, 2022 7:59 PM EST38$0.9672
Jun 13, 2022 7:59 PM EST10$0.9672

Neoleukin Therapeutics, Inc (NLTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520186835/0001193125-20-186835-index.htm
2018-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000003877718000043/0000038777-18-000043-index.htm
2019-01-25SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000003877719000011/0000038777-19-000011-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000008025518002567/0000080255-18-002567-index.htm
2018-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000008025518002782/0000080255-18-002782-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000008025519002663/0000080255-19-002663-index.htm
2018-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000021545718000086/0000215457-18-000086-index.htm
2019-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319022733/0000899243-19-022733-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319023329/0000899243-19-023329-index.htm
2019-09-134/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319023581/0000899243-19-023581-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319025571/0000899243-19-025571-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319025572/0000899243-19-025572-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319025573/0000899243-19-025573-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319025575/0000899243-19-025575-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000089924319029824/0000899243-19-029824-index.htm
2018-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000093583618000408/0000935836-18-000408-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000093583619000119/0000935836-19-000119-index.htm
2019-12-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000093583619000673/0000935836-19-000673-index.htm
2019-11-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404644/000110465919065138/0001104659-19-065138-index.htm
2019-12-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404644/000110465919075093/0001104659-19-075093-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000110465920043861/0001104659-20-043861-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000114420418009001/0001144204-18-009001-index.htm
2019-08-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404644/000114420419038249/0001144204-19-038249-index.htm
2019-08-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404644/000114420419039617/0001144204-19-039617-index.htm
2017-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312517336565/0001193125-17-336565-index.htm
2017-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312517336569/0001193125-17-336569-index.htm
2017-12-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312517370193/0001193125-17-370193-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518004980/0001193125-18-004980-index.htm
2018-02-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518037145/0001193125-18-037145-index.htm
2018-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404644/000119312518079210/0001193125-18-079210-index.htm
2018-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518079220/0001193125-18-079220-index.htm
2018-03-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404644/000119312518079227/0001193125-18-079227-index.htm
2018-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404644/000119312518079240/0001193125-18-079240-index.htm
2018-03-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404644/000119312518095204/0001193125-18-095204-index.htm
2018-03-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404644/000119312518095207/0001193125-18-095207-index.htm
2018-04-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1404644/000119312518107649/0001193125-18-107649-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518155357/0001193125-18-155357-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312518155359/0001193125-18-155359-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518158253/0001193125-18-158253-index.htm
2018-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518159868/0001193125-18-159868-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518188804/0001193125-18-188804-index.htm
2018-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518204812/0001193125-18-204812-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518214778/0001193125-18-214778-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312518242081/0001193125-18-242081-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518242083/0001193125-18-242083-index.htm
2018-09-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518269260/0001193125-18-269260-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312518320293/0001193125-18-320293-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312518320304/0001193125-18-320304-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404644/000119312519066506/0001193125-19-066506-index.htm
2019-04-1510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404644/000119312519106596/0001193125-19-106596-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312519139021/0001193125-19-139021-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312519209916/0001193125-19-209916-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519213526/0001193125-19-213526-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519218513/0001193125-19-218513-index.htm
2019-09-20PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1404644/000119312519250120/0001193125-19-250120-index.htm
2019-10-02DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404644/000119312519260378/0001193125-19-260378-index.htm
2019-10-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404644/000119312519260380/0001193125-19-260380-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519260762/0001193125-19-260762-index.htm
2019-10-118-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519266322/0001193125-19-266322-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000119312519290610/0001193125-19-290610-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519290613/0001193125-19-290613-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519292399/0001193125-19-292399-index.htm
2019-11-15S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404644/000119312519293455/0001193125-19-293455-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519306819/0001193125-19-306819-index.htm
2019-12-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519316287/0001193125-19-316287-index.htm
2019-12-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1404644/000119312519316290/0001193125-19-316290-index.htm
2019-12-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1404644/000119312519317636/0001193125-19-317636-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519317938/0001193125-19-317938-index.htm
2019-12-27SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404644/000119312519324905/0001193125-19-324905-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312519326026/0001193125-19-326026-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520005970/0001193125-20-005970-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000119312520035504/0001193125-20-035504-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000119312520035513/0001193125-20-035513-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404644/000119312520038492/0001193125-20-038492-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520047316/0001193125-20-047316-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520067891/0001193125-20-067891-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520071537/0001193125-20-071537-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/0001193125-20-071545-index.htm
2020-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404644/000119312520071627/0001193125-20-071627-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520080642/0001193125-20-080642-index.htm
2020-03-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404644/000119312520083231/0001193125-20-083231-index.htm
2020-03-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404644/000119312520083232/0001193125-20-083232-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520104856/0001193125-20-104856-index.htm
2020-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404644/000119312520109381/0001193125-20-109381-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520109503/0001193125-20-109503-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520156617/0001193125-20-156617-index.htm
2020-07-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1404644/000119312520185196/0001193125-20-185196-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1404644/000119312520186822/0001193125-20-186822-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520186835/0001193125-20-186835-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520208195/0001193125-20-208195-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000119312520242679/0001193125-20-242679-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019255/0001209191-18-019255-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019256/0001209191-18-019256-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019258/0001209191-18-019258-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019259/0001209191-18-019259-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019260/0001209191-18-019260-index.htm
2018-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118019267/0001209191-18-019267-index.htm
2018-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118020680/0001209191-18-020680-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118028968/0001209191-18-028968-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118028974/0001209191-18-028974-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118028979/0001209191-18-028979-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118028983/0001209191-18-028983-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118028988/0001209191-18-028988-index.htm
2018-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118030711/0001209191-18-030711-index.htm
2018-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118046094/0001209191-18-046094-index.htm
2018-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118046095/0001209191-18-046095-index.htm
2018-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118046097/0001209191-18-046097-index.htm
2018-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919118046098/0001209191-18-046098-index.htm
2020-03-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120019429/0001209191-20-019429-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120019430/0001209191-20-019430-index.htm
2020-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120027679/0001209191-20-027679-index.htm
2020-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120027683/0001209191-20-027683-index.htm
2020-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120027689/0001209191-20-027689-index.htm
2020-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120027694/0001209191-20-027694-index.htm
2020-06-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120033538/0001209191-20-033538-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120033543/0001209191-20-033543-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120046339/0001209191-20-046339-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120046342/0001209191-20-046342-index.htm
2020-09-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120049960/0001209191-20-049960-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120049966/0001209191-20-049966-index.htm
2020-10-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120055394/0001209191-20-055394-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000120919120055395/0001209191-20-055395-index.htm
2019-08-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000121390019015382/0001213900-19-015382-index.htm
2019-08-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000121390019015385/0001213900-19-015385-index.htm
2019-08-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000121390019015387/0001213900-19-015387-index.htm
2019-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000121390019015390/0001213900-19-015390-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000156459020021546/0001564590-20-021546-index.htm
2020-05-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404644/000156459020021550/0001564590-20-021550-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000156459020021903/0001564590-20-021903-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000156459020021920/0001564590-20-021920-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404644/000156459020039662/0001564590-20-039662-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404644/000156459020039671/0001564590-20-039671-index.htm
2018-05-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859918000485/0001638599-18-000485-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859919000803/0001638599-19-000803-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859919000919/0001638599-19-000919-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859919001057/0001638599-19-001057-index.htm
2020-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404644/000163859920000417/0001638599-20-000417-index.htm
2018-04-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1404644/999999999518000773/9999999995-18-000773-index.htm
2018-08-31CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1404644/999999999718007549/9999999997-18-007549-index.htm

Neoleukin Therapeutics, Inc (NLTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neoleukin Therapeutics, Inc (NLTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2029%
Institutional Ownership: 6622%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-05-14DANIEL J LEVITTDirectorSell3,906.0012.6749,489.020.00https://www.sec.gov/Archives/edgar/data/1404644/000120919118030711/0001209191-18-030711-index.htm
2018-03-15Lloyd MacKenzieChief Operating OfficerSell1,302.0014.6319,048.780.00https://www.sec.gov/Archives/edgar/data/1404644/000120919118020680/0001209191-18-020680-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy209,382.003.02633,254.9210,054,723.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy50,436.003.15159,019.6610,105,159.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-06BROS. ADVISORS LP BAKERDirectorBuy855.002.832,422.041,170,550.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-06BROS. ADVISORS LP BAKERDirectorBuy5,932.002.8516,887.811,176,482.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy531.002.961,570.491,177,013.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy18,943.003.0257,291.211,195,956.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy4,564.003.1514,389.841,200,520.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-12-20BROS. ADVISORS LP BAKERDirectorBuy2,767,505.008.4023,247,042.0012,872,664.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919001057/0001638599-19-001057-index.htm
2018-03-15Lloyd MacKenzieChief Operating OfficerBuy1,302.0010.5613,749.121,302.00https://www.sec.gov/Archives/edgar/data/1404644/000120919118020680/0001209191-18-020680-index.htm
2019-12-20BROS. ADVISORS LP BAKERDirectorBuy250,037.008.402,100,310.801,450,557.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919001057/0001638599-19-001057-index.htm
2019-12-20JONATHAN G DRACHMANPresident and CEOBuy119,047.008.40999,994.802,198,686.00https://www.sec.gov/Archives/edgar/data/1404644/000089924319029824/0000899243-19-029824-index.htm
2019-12-20BROS. ADVISORS LP BAKERDirectorSell1,160,148.00290,409.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919001057/0001638599-19-001057-index.htm
2019-12-20BROS. ADVISORS LP BAKERDirectorSell9,765,333.003,107,331.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919001057/0001638599-19-001057-index.htm
2019-08-08JONATHAN G DRACHMANPresident and CEOBuy334,428.00334,428.00https://www.sec.gov/Archives/edgar/data/1404644/000121390019015390/0001213900-19-015390-index.htm
2018-05-14DANIEL J LEVITTDirectorBuy3,906.0010.5641,247.363,906.00https://www.sec.gov/Archives/edgar/data/1404644/000120919118030711/0001209191-18-030711-index.htm
2020-03-27Redmile Group, LLC10% Share HolderBuy50,000.009.21460,395.003,916,579.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-03-30Redmile Group, LLC10% Share HolderBuy29,800.009.91295,169.003,946,379.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-03-30Redmile Group, LLC10% Share HolderBuy2,700.0010.2727,740.883,949,079.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-03-31Redmile Group, LLC10% Share HolderBuy22,500.0010.18229,079.253,971,579.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-03-31Redmile Group, LLC10% Share HolderBuy7,500.0010.7180,309.253,979,079.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-01Redmile Group, LLC10% Share HolderSell200.0011.872,373.004,011,745.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-01Redmile Group, LLC10% Share HolderSell9,634.0011.06106,567.454,011,945.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-01Redmile Group, LLC10% Share HolderBuy33,500.0010.95366,764.704,012,579.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-01Redmile Group, LLC10% Share HolderBuy9,000.0011.65104,865.304,021,579.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-02Redmile Group, LLC10% Share HolderSell100.0011.821,182.004,041,211.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-02Redmile Group, LLC10% Share HolderSell9,734.0011.30110,032.164,041,311.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-02Redmile Group, LLC10% Share HolderBuy38,300.0011.36435,107.154,050,045.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2020-04-02Redmile Group, LLC10% Share HolderBuy1,000.0011.8511,850.604,051,045.00https://www.sec.gov/Archives/edgar/data/1404644/000110465920043863/0001104659-20-043863-index.htm
2019-09-09JONATHAN G DRACHMANOfficerBuy76,822.002.85218,558.59411,250.00https://www.sec.gov/Archives/edgar/data/1404644/000089924319023329/0000899243-19-023329-index.htm
2019-09-10JONATHAN G DRACHMANOfficerBuy36,742.003.08113,290.28447,992.00https://www.sec.gov/Archives/edgar/data/1404644/000089924319023329/0000899243-19-023329-index.htm
2019-09-11JONATHAN G DRACHMANOfficerBuy136,436.003.30449,897.71584,428.00https://www.sec.gov/Archives/edgar/data/1404644/000089924319023329/0000899243-19-023329-index.htm
2019-08-08JONATHAN G DRACHMANPresident and CEOBuy7,428.007,428.00https://www.sec.gov/Archives/edgar/data/1404644/000121390019015390/0001213900-19-015390-index.htm
2019-08-06BROS. ADVISORS LP BAKERDirectorBuy9,445.002.8326,755.809,773,904.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-06BROS. ADVISORS LP BAKERDirectorBuy65,568.002.85186,665.549,839,472.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm
2019-08-07BROS. ADVISORS LP BAKERDirectorBuy5,869.002.9617,358.159,845,341.00https://www.sec.gov/Archives/edgar/data/1404644/000163859919000703/0001638599-19-000703-index.htm